WSJ : McDonald's Faces 'Millennial' Challenge ( stock flat in pre open)

McDonald's Faces 'Millennial' Challenge
Customers in Their 20s and 30s Are Defecting to Fast-Casual Restaurants Like Chipotle, Five Guys
Behind McDonald's Corp.'s MCD -0.08% worst slump in a decade is a trend that may auger even tougher times ahead: The Golden Arches is losing its luster with younger consumers.

The world's largest restaurant company by revenue earlier this month reported its sharpest monthly decline in global same-store sales since early 2003, adjusted for calendar irregularities.

In the U.S., with more than 40% of McDonald's 35,000-plus global locations, sales at restaurants open at least 13 months have been flat or falling for most of the past year.

The hamburger giant on Friday announced it was replacing the head of its U.S. division for the second time in less than two years. The company tapped a former executive, Mike Andres, to take the helm of the domestic business—another sign that the company is trying to revive its fortunes at home.

McDonald's stock has traded in a relatively narrow range in the nearly 26 months since Chief Executive Don Thompson took the helm, while the share prices of many of its rivals have soared. McDonald's shares are down about 2% since the start of the year, closing at $94.45 Friday.

Demographics help shed light on McDonald's woes. Data compiled for The Wall Street Journal by restaurant consultancy Technomic Inc. point to an age problem for the chain. Customers in their 20s and 30s—long a mainstay of McDonald's business—are defecting to competitors, in particular so-called fast-casual restaurants like Chipotle Mexican Grill Inc. and gourmet-burger chain Five Guys Holdings LLC.

Increasingly, younger diners are seeking out fresher, healthier food and chains that offer customizable menu options for little more than the price of a combo meal.

The percentage of people age 19 to 21 in the U.S. who visited McDonald's monthly has fallen by 12.9 percentage points since the beginning of 2011, according to Technomic, while the percentage of customers age 22 to 37 visiting monthly during that period has been flat.

During the same period, the percentage of 19-to-21-year-olds increased their monthly visits to fast-casual restaurants by 2.3 percentage points, and 22-to-37-year-olds by 5.2 percentage points, Technomic says.

Alec Petersen, a 21-year-old from Hoboken, N.J., rarely visits McDonald's anymore. "I do have nostalgic memories of McDonald's, but Chipotle has much better quality food, or at least it feels like they do," said Mr. Petersen, who recently graduated from Duke University.

McDonald's says new items like its McWrap sandwiches—chicken and vegetables rolled in tortillas—are helping to woo millennials, consumers in their midteens to mid-30s. The Oak Brook, Ill.-based company also is trying to enhance its credibility with young customers by marketing more on digital channels and testing mobile ordering and payment.

"The millennial generation has a wider range of choices than any generation before them," McDonald's Global Chief Brand Officer Steve Easterbrook said in an interview. "They're promiscuous in their brand loyalty. It makes it harder work for all of us to earn the loyalty of the millennial generation."

McDonald's U.S. sales struggles have also been compounded recently by other woes challenging Mr. Thompson, a 24-year company veteran who became CEO in July 2012 after a decade of strong growth.

In China, a former bright spot, sales have fallen after authorities last month accused a key supplier of selling expired meat. McDonald's said the problem drove sales at existing locations in its Asia/Pacific, Middle East and Africa region down by 7.3% in July.

In Russia, amid heightened tension between the West and Moscow over the conflict in Ukraine, authorities last week closed some McDonald's restaurants in Moscow for alleged sanitary violations and are now inspecting its outlets across Russia.

Meanwhile, at home, it also is grappling with growing worker protests calling for higher wages and the right to organize. And the National Labor Relations Board last month determined that McDonald's could be treated as a joint employer with its franchisees in labor complaints, which could make the company liable for the actions of its franchisees.

McDonald's has acknowledged other recent missteps, including an overcrowded menu that slowed service. Executives have said that the nearly 60-year-old company has lost relevance with consumers. In June it set up a "learning lab" at a restaurant in Laguna Niguel, Calif., to better understand what people want and to experiment with customizable burgers.

The fast-casual concept took shape in the 1990s, melding the fresher ingredients and custom ordering of table-service restaurants with the convenience of fast-food joints.

Other examples include Panera Bread Co. PNRA +0.14% , Noodles NDLS -1.36% & Co., and Corner Bakery Cafe. The chains appeal to younger consumers who came of age at a time of skepticism of fast food—evident in the 2001 book "Fast Food Nation" and the 2004 documentary "Super Size Me"—and a burgeoning foodie culture that emphasizes fresh ingredients.

A decade ago, there were 9,000 fast-casual restaurants in the U.S., versus nearly 14,000 McDonald's. Now, fast-casual restaurants number more than 21,000, according to Technomic, while McDonald's U.S. restaurant count has risen only slightly.

Chipotle, founded in 1993, today has more than 1,600 U.S. outlets and a market value of about $21 billion. Five Guys, which boasts that it offers more than 250,000 ways to order a burger, has grown to more than 1,000 outlets since it was founded 28 years ago.

Last month Consumer Reports magazine said that in a survey of more than 32,000 subscribers, readers rated McDonald's burgers as the worst-tasting of 20 rival burger chains.

The magazine cited the preferences of younger consumers as a main factor. "Diners, especially younger adults in the millennial generation, may be more willing to go out of their way to get a tasty meal," Consumer Reports said.

McDonald's responded that it is "proud to serve 27 million customers" daily in the U.S., and "It's important for us to listen to their feedback as it helps us better meet their needs and expectations."

Fast-casual chains like Chipotle and Panera also have cultivated an image of social responsibility that appeals to many young people, such as by offering organic ingredients and pork from "naturally raised" pigs

Millennials "want to buy into a brand not just from it," said Mr. Easterbrook. He said McDonald's is developing mobile apps that will enable people to access information about the company's social responsibility. "What we've got to do is find interesting and engaging ways to share that information with millennials, not old-fashioned corporate lecturing.

Yet adjusting to the new competitive threats is tricky for such a giant and its huge, complex supply chain. Fresher ingredients and more customizable orders could appeal to some customers but alienate others by driving up prices or slowing preparation times.

Some analysts and investors feel McDonald's is simply too big to make meaningful changes within its U.S. restaurants. Scott Rothbort, president of LakeView Asset Management, who sold his McDonald's shares earlier this year, says the company needs to do something bold to juice growth, such as acquiring a fast-casual chain.

McDonald's has been a player in the fast-casual segment before. It bought a stake in Chipotle in 1998, which it later increased before selling it eight years later for $1.5 billion.

"McDonald's has an image problem and it needs to set out a vision of what it wants to be," said Dieter Waizenegger, executive director of CtW Investment Group, which advises pension funds that have holdings in McDonald's. "They need to chart a new course."

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
: GEF -6.2%, QIHU -3.9%.

Other news: RGDO -44% (permanently halts REGULATE-PCI clinical trial), CGEN -1.2% (disclosed it appointed Ari Krashin as Chief Financial Officer effective as of September 9, 2014), OKS -0.9% (files for $650 mln offering of common units representing limited partner interests).

Analyst comments: STLD -1.7% (downgraded to Neutral at from Outperform Credit Suisse)
.

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: MY +4.8%.

M&A news: ITMN +36% (enters into a definitive merger agreement for Roche (RHHBY) to fully acquire InterMune at a price of $74.00 per share), THI +17% (Tim Hortons and Burger King (BKW) confirm talks regarding potential strategic transaction), BKW +16.5% (Tim Hortons and Burger King (BKW) confirm talks regarding potential strategic transaction), TLM +1% (reports indicate Iraq Kurdistan sale process is proceeding).

Select alt energy related names showing strength: BIOF +5.2%, CPST +2.4%, FCEL +1.9%, PLUG +1%.

Other news: DGLY +19.3% (Pres Obama reportedly to initiate an audit on police military equipment), PZG +11.1% (announces results of PEA for its 100%-owned San Miguel gold and silver project in Chihuahua State), ADXS +7.7% (Co and Merck (MRK) form collaboration to evaluate investigational combination of two novel immunotherapy candidates for advanced prostate cancer), AMPE+7% (issues letter to shareholders in regard to the STEP study and co's plans for the Ampion BLA), ANN +6.6% (Co responds to activist activity, reports over weekend urging to co to sell itself), DRL +4% (Puerto Rico Department of Justice and Treasury issued joint statement late Friday), AKS +2.8% (X peer, X upgraded at CS), EXAS +2.6% (announces Mayo Clinic as first healthcare system to offer Cologuard), TASR +2.5% (Pres Obama reportedly to initiate an audit on police military equipment), KING +2.1% (still checking), LRAD +2% (Pres Obama reportedly to initiate an audit on police military equipment), MSG +1.9% (JAT Capital Management discloses 6.73% active stake in 13D filing), ICPT +1.4% (may be related to ITMN takeover), LJPC +1.2% (Announces First Patient Enrolled in Clinical Trial of LJPC-501 in Hepatorenal Syndrome).

Analyst comments: XGTI +13.4% (initiated with a Buy at ROTH Capital), X +3.4% (upgraded to Outperform from Underperform at Credit Suisse), ELGX +3.1% (upgraded to Buy from Neutral at BTIG Research), AAVL +2.7% (initiated with a Buy at Jefferies), JCP +2.5% (may be attributed to positive JPMorgan comments), TNP +1.6% (initiated with a Outperform at Wells Fargo), CBOE +1.4% (upgraded to Outperform from Mkt Perform at Raymond James), WPX +1.3% (upgraded to Sector Outperform at Howard Weil)

L'Express : Vivendi: Telefonica would be willing to revise its offer for GVT.

Vivendi: Telefonica serait prêt à revoir son fils Offre sur GVT.

According to the Italian daily Il Messaggero, Telefonica would be determined to buy GVT, the Brazilian assets of Vivendi that is not officially for sale, but the group fra ..

According to the Italian daily Il Messaggero, Telefonica would be determined to buy GVT, the Brazilian assets of Vivendi that is not officially for sale, but the French group seeks to separate for months as part of its strategic change. The initial offer of 6.7 billion euros of Spanish operator (money payable 60% in cash and 40% in securities Vivo brand under which it operates in Brazil) was the country last week by Telecom Italia, the proposal would be according to the news agency Ansa scrutinized by Vincent Bolloré.
The Chairman of the Supervisory Board of Vivendi has many over from the other side of the Alps. As such, the Alpine group might have a head start on this.
Telefonica, however, seems way willing to give up and could revise its offer clearly upward. The operator and propose € 8 billion to acquire GVT.
"Vivendi has the advantage of not being in a hurry, what allow him to raise the stakes', noted last week Aurel BGC. What judge credibility to the hypothesis of new twists on this.
In exchange, the possible escalation of Telefonica does however hardly react, the Vivendi title slightly underperforming the market with a gain of about 0.7% to € 19.6.

>>> US Early premarket gappers

Early premarket gappers
Gapping up: ITMN +35%, THI +17%, BIOF +5.1%, ICPT +4.5%, MY +4.2%, JCP +2.7%, X +1.8%, CELG +1.2%, PLUG +1.2%, NFLX +1.0%

Gapping down: RGDO -26%, QIHU -4.9%, PHMD -2.3%, JBLU -1.1%, CGEN -1.1%

>>> U.S. approval of Merck cancer immunotherapy expected soon

(Reuters) - U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

If approved by the Food and Drug Administration, the drug would be the first in a promising new class designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumors to evade disease-fighting cells.

Companies including Bristol-Myers Squibb, Roche Holding AG and AstraZeneca Plc are racing to develop similar treatments for a variety of cancers. Some analysts expect the new class could generate more than $30 billion in annual sales worldwide by 2025.

The FDA is slated to decide on New Jersey-based Merck's application no later than October 28, but sources said the agency could give its approval within coming weeks. The sources, who spoke on condition of anonymity because they were not authorized to discuss the FDA's plans, also acknowledged that the early approval was not guaranteed.

A spokeswoman for the FDA said the agency cannot discuss the status of applications.

Merck is first seeking to sell its PD-1 drug for patients whose skin cancer does not respond to treatment with Yervoy, a Bristol-Myers immunotherapy that targets a different part of the immune system.

Studies have shown that pembrolizumab shrinks tumors in about a third of patients with late-stage melanoma, a disease that kills around 10,000 Americans each year.

"My hope is that over the next five to 10 years, we will be curing over half of melanoma patients," said Dr Steven O'Day, director of the Los Angeles Skin Cancer Institute.

Dr Antoni Ribas, professor of hematology-oncology at the University of California, Los Angeles, and a pembrolizumab trial lead investigator, said having the drug on the market will be "a big deal" for patients who currently have few options.

"If we have pembro approved, it makes a big difference. About a third of those patients will have a chance of a durable, long-lasting response," he said.

Merck and its rivals are also studying PD-1 drugs as a treatment for several types of cancer. Lung cancer, which kills nearly 160,000 Americans annually, is seen as the biggest sales opportunity for the new class of treatments.

Most current oncology treatments seek to kill cancer cells directly whereas immuno-oncology drugs unleash the body's own ability to recognize and destroy cancer cells, which medical researchers say could have broader reach.

A potential risk is that stimulating the immune system could cause side effects ranging from mild rash to more serious liver problems or colitis.

FIRST IN LUNG CANCER

Bristol hopes to be first to the market with an immunotherapy for lung cancer. It is studying its experimental PD-1 drug, nivolumab, both as a stand-alone therapy and in combination with Yervoy, also known as ipilimumab, which inhibits a protein called CTLA-4.

"We believe a combination of immuno-oncology agents represents the best chance for patients to achieve long-term survival," said Michael Giordano, head of development, oncology and immunology, at Bristol.

He said Bristol is submitting lung cancer data to the FDA on a rolling basis and expects to complete its application by year-end, which "certainly gives us confidence that we are in the lead, potentially first in lung cancer."

Merck is not studying pembrolizumab in combination with its own experimental drugs, but does have studies underway with drugs from Amgen, Novartis and others. Merck is also conducting a study of the PD-1 drug in combination with its older melanoma drug Sylatron.

"In oncology, combinations typically provide superior benefit," Roger Perlmutter, head of research at Merck, said in a June interview. "But picking them is tricky. We first need to understand it as monotherapy."

Perlmutter could not be reached for comment regarding pembrolizumab's approval timeline.

Roche, granted FDA "breakthrough therapy" designation in June for its experimental drug MPDL3280A as a treatment for bladder cancer, is conducting a range of trials in various types of cancer, including combination treatment studies.

"We have a broad pipeline of targeted therapies," said Sandra Horning, chief medical officer at Roche's Genentech unit.

(BFW) Saudi Aramco Plans to Invest More Than $40b/Year For Next Decade

--> could help a bit the sector of Oil services

Saudi Aramco Plans to Invest More Than $40b/Year For Next Decade
2014-08-25 09:36:13.278 GMT


By Mikael Holter
Aug. 25 (Bloomberg) -- Saudi Aramco plans to maintain
maximum oil output capacity at 12m b/d, aims to double gas
production, CEO Khalid Al-Falih said in Stavanger today.
* CEO says shale oil/gas, ‘one of best things’ to have
happened; have kept prices in a band
* Geopolitical events clouding outlook, costs/risk likely to
put downward pressure on supply; also ‘bullish factors’ that
offset that picture, Al-Falih says
* Company’s project costs have about doubled during last 10
years; recruitment has become ‘acute challenge’

Link to Company News:{131861Z AB <Equity> CN <GO>}

For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}

To contact the reporter on this story:
Mikael Holter in Oslo at +47-22-00-8209 or
mholter2@bloomberg.net

To contact the editor responsible for this story:
Alastair Reed at +47-22-00-8212 or
areed12@bloomberg.net